CLINICAL UNIT FOR THE ANGIOGRAPHIC TRIAL IN WOMEN

这项计划的目的是评估荷尔蒙替代 治疗和/或抗氧化剂治疗将稳定或抑制病情进展， 并诱导女性冠状动脉斑块消退。 阶段1(8个月)包括规划和组织研究方案， 操作手册和数据表格。协议开发将需要 大约6个月。在协议开发之后，将有一个 研究活动中断了大约2个月。在此期间， 参与中心将根据以下条件准备和提交修订后的成本提案 关于实际的协议。第11阶段(4年)将用于招募患者 和病人的随访。第111阶段(6个月)用于数据分析。

The purpose of this program is to assess whether hormonal replacement therapy and/or antioxidant treatment will stabilize or inhibit progression, and induce regression of coronary plaques in women. Phase 1(8 months) comprises planning and organizing the Study Protocols, Manual of Operations, and data forms. Protocol Development will take approximately 6 months. After Protocol Development, there will be an approximate 2 month hiatus in activity on the study. During this time, the participating centers will prepare and submit revised cost proposals based on the actual protocol. Phase 11(4 years) will be for patient recruitment and patient follow-up. Phase 111(6 months) is for data analysis.